These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33392398)

  • 1. Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis.
    Miccio JA; Talcott WJ; Patel T; Park HS; Cecchini M; Salem RR; Khan SA; Stein S; Kortmansky JS; Lacy J; Narang A; Herman J; Jabbour SK; Hallemeier CL; Johung K; Jethwa KR
    Clin Transl Radiat Oncol; 2021 Mar; 27():15-23. PubMed ID: 33392398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer.
    Mokhtech M; Miccio JA; Johung K; Cecchini M; Stein S; Narang AK; Herman JM; Kunstman J; Haddock MG; Anker CJ; Jabbour S; Hallemeier CL; Jethwa KR
    Am J Clin Oncol; 2022 Nov; 45(11):450-457. PubMed ID: 36318696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis.
    Kamarajah SK; Sonnenday CJ; Cho CS; Frankel TL; Bednar F; Lawrence TS; Nathan H
    Ann Surg; 2021 Mar; 273(3):587-594. PubMed ID: 30817352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic Cancer with Vascular Involvement: Adherence to Current Standard-of-Care Associated with Improved Survival.
    Mohamed A; Nicolais L; Fitzgerald TL
    Am Surg; 2023 Dec; 89(12):5535-5544. PubMed ID: 36854081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era.
    Hue JJ; Dorth J; Sugumar K; Hardacre JM; Ammori JB; Rothermel LD; Saltzman J; Mohamed A; Selfridge JE; Bajor D; Winter JM; Ocuin LM
    Am Surg; 2021 Sep; 87(9):1386-1395. PubMed ID: 34382877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation.
    Anderson JD; Wan W; Kaplan BJ; Myers J; Fields EC
    J Gastrointest Oncol; 2016 Dec; 7(6):1004-1010. PubMed ID: 28078125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Radiotherapy is Associated with R0 Resection and Improved Survival for Patients with Extremity Soft Tissue Sarcoma Undergoing Surgery: A National Cancer Database Analysis.
    Gingrich AA; Bateni SB; Monjazeb AM; Darrow MA; Thorpe SW; Kirane AR; Bold RJ; Canter RJ
    Ann Surg Oncol; 2017 Oct; 24(11):3252-3263. PubMed ID: 28741123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Better Defining the Role of Total Neoadjuvant Radiation: Changing Paradigms in Locally Advanced Pancreatic Cancer.
    Vidri RJ; Vogt AO; Macgillivray DC; Bristol IJ; Fitzgerald TL
    Ann Surg Oncol; 2019 Oct; 26(11):3701-3708. PubMed ID: 31286306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative downstaging of pancreatic cancer is associated with improved survival after multi-agent chemotherapy, but not after radiation.
    Nicolais L; Brown AW; Mohamed A; Clark DE; Fitzgerald TL
    Surg Oncol; 2023 Jun; 48():101939. PubMed ID: 37116276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
    Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-agent neoadjuvant chemotherapy improves response and survival in patients with resectable pancreatic cancer.
    Blinn P; Shridhar R; Maramara T; Huston J; Meredith K
    J Gastrointest Oncol; 2020 Oct; 11(5):1078-1089. PubMed ID: 33209499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
    Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
    PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma.
    Khattab A; Patruni S; Abel S; Hasan S; Ludmir EB; Finley G; Monga D; Wegner RE; Verma V
    J Gastrointest Oncol; 2019 Oct; 10(5):918-927. PubMed ID: 31602330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant therapy and pancreatic cancer: a national cancer database analysis.
    Shridhar R; Takahashi C; Huston J; Meredith KL
    J Gastrointest Oncol; 2019 Aug; 10(4):663-673. PubMed ID: 31392047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity-matched National Cancer Database analysis.
    Kamarajah SK; Bednar F; Cho CS; Nathan H
    Cancer; 2021 Apr; 127(8):1266-1274. PubMed ID: 33320344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers.
    David JM; Kim S; Placencio-Hickok VR; Torosian A; Hendifar A; Tuli R
    Adv Radiat Oncol; 2019; 4(2):302-313. PubMed ID: 31011675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.
    Chopra A; Zenati M; Hogg ME; Zeh HJ; Bartlett DL; Bahary N; Zureikat AH; Beane JD
    Ann Surg Oncol; 2021 Nov; 28(12):7759-7769. PubMed ID: 34027585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
    Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
    Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.